BioCentury | Sep 4, 2020
Emerging Company Profile

Lumen growing lean, green biologics with $16M series B and Gates funding

...toxins with a recombinant endolysin —a phage...
BioCentury | May 26, 2020
Distillery Therapeutics

Blocking flu with phage capsid nanoparticles

...DISEASE CATEGORY: Infectious disease INDICATION: Influenza virus Nanoparticles derived from phage capsids could prevent influenza infection...
BioCentury | Apr 3, 2020
Product Development

COVID-19 roundup: Amgen taps Adaptive as its antibody therapeutic partner; plus Alnylam-Vir’s siRNA targets, Ansun’s data and more

...infections in immunodeficient patients (see “China-Heavy Syndicate Backs Series B for Antiviral Play Ansun” ). Phage-derived...
...prevent the virus from interacting with host cells. Dependent on physical geometry, capsids from the phage...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...scientific director of the immunopathology lab at Fred Hutchinson Cancer Research Center. Sensei is developing phage-based...
BioCentury | Mar 14, 2020
Translation in Brief

A peptide fusion blocker for multiple coronaviruses, the cryo-EM structure of SARS-CoV-2 main protease, plus Locus, Excision and Harvard-Dana-Farber

...CRISPR-expressing phage lowered fecal C. diff burden by about 10-fold compared with vehicle or wild-type phage...
BioCentury | Jan 8, 2020
Finance

With $69M D round, Adagene looks to Phase II for solid, blood cancers

...on its Dynamic Precision Library platform, which combines computational design, machine learning and high throughput phage...
BioCentury | Dec 20, 2019
Tools & Techniques

Editing bacterial resistance via gene drives

...combine Pro-AG with a platform for dissemination between bacteria such as a conjugal plasmid or phage/phagemid...
BioCentury | Nov 15, 2019
Preclinical News

Nov. 14 Preclinical Quick Takes: Gut microbe-targeting phage for alcoholic liver disease; plus Cellectis, Biomica, University of Michigan and Rubius

Bacteriophages for alcoholic liver disease In a study described in Nature , University of California San Diego researchers identified a strain of gut microbiome member Enterococcus faecalis that expresses the exotoxin cytolysin as a target for...
BioCentury | Oct 15, 2019
Company News

Management tracks: Gilead taps Dickinson for CFO job; plus Checkmate, BiomX, Anixa and Trio

...VP, regulatory affairs and quality assurance at Tarveda Therapeutics Inc. BiomX Ltd. , which develops phage...
BioCentury | Sep 26, 2019
Financial News

ZielBio raises $25M series A to advance two new cancer targets

...content data analytics. The platform starts with a functional screen using display technologies such as phage...
Items per page:
1 - 10 of 618
BioCentury | Sep 4, 2020
Emerging Company Profile

Lumen growing lean, green biologics with $16M series B and Gates funding

...toxins with a recombinant endolysin —a phage...
BioCentury | May 26, 2020
Distillery Therapeutics

Blocking flu with phage capsid nanoparticles

...DISEASE CATEGORY: Infectious disease INDICATION: Influenza virus Nanoparticles derived from phage capsids could prevent influenza infection...
BioCentury | Apr 3, 2020
Product Development

COVID-19 roundup: Amgen taps Adaptive as its antibody therapeutic partner; plus Alnylam-Vir’s siRNA targets, Ansun’s data and more

...infections in immunodeficient patients (see “China-Heavy Syndicate Backs Series B for Antiviral Play Ansun” ). Phage-derived...
...prevent the virus from interacting with host cells. Dependent on physical geometry, capsids from the phage...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...scientific director of the immunopathology lab at Fred Hutchinson Cancer Research Center. Sensei is developing phage-based...
BioCentury | Mar 14, 2020
Translation in Brief

A peptide fusion blocker for multiple coronaviruses, the cryo-EM structure of SARS-CoV-2 main protease, plus Locus, Excision and Harvard-Dana-Farber

...CRISPR-expressing phage lowered fecal C. diff burden by about 10-fold compared with vehicle or wild-type phage...
BioCentury | Jan 8, 2020
Finance

With $69M D round, Adagene looks to Phase II for solid, blood cancers

...on its Dynamic Precision Library platform, which combines computational design, machine learning and high throughput phage...
BioCentury | Dec 20, 2019
Tools & Techniques

Editing bacterial resistance via gene drives

...combine Pro-AG with a platform for dissemination between bacteria such as a conjugal plasmid or phage/phagemid...
BioCentury | Nov 15, 2019
Preclinical News

Nov. 14 Preclinical Quick Takes: Gut microbe-targeting phage for alcoholic liver disease; plus Cellectis, Biomica, University of Michigan and Rubius

Bacteriophages for alcoholic liver disease In a study described in Nature , University of California San Diego researchers identified a strain of gut microbiome member Enterococcus faecalis that expresses the exotoxin cytolysin as a target for...
BioCentury | Oct 15, 2019
Company News

Management tracks: Gilead taps Dickinson for CFO job; plus Checkmate, BiomX, Anixa and Trio

...VP, regulatory affairs and quality assurance at Tarveda Therapeutics Inc. BiomX Ltd. , which develops phage...
BioCentury | Sep 26, 2019
Financial News

ZielBio raises $25M series A to advance two new cancer targets

...content data analytics. The platform starts with a functional screen using display technologies such as phage...
Items per page:
1 - 10 of 618